Pharmaceuticals
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therapeutics HONG KONG, Germantown, Md. and SUZHOU, China, Jan. 24, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a l...
2024-01-24 17:49
3482
Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide
* Oral ecnoglutide was safe and well tolerated with gastrointestinal side effects as the most commonly reported adverse events * Study participants receiving up to 30 mg oral ecnoglutide once-daily for 6 weeks achieved a mean body weight reduction of -6.8% from baseline, compared to -0.9% for...
2024-01-24 10:00
3674
INTREPID Alliance Releases Review of Antiviral Compounds in Clinical Development to Contribute to Collaborative Efforts in Pandemic Preparedness
Global landscape analysis identifies strengths and gaps in R&D pipeline to inform international pandemic preparedness efforts ROME and CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire/ -- The INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating the devel...
2024-01-24 08:22
2036
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301) for subcutaneous fat reduction. "We are all delighted to see CBL-514 showing its ...
2024-01-23 21:12
2879
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis - Primary efficacy endpoints: * NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD A...
2024-01-23 12:17
4073
Extensive R&D Capabilities：ICP DAS - BMP to Showcase a Broad Range of Medical-Grade TPU at MD&M West 2024, U.S.
HSINCHU, Jan. 23, 2024 /PRNewswire/ -- ICP DAS – BMP, Asia's first medical-grade thermoplastic polyurethane (TPU) supplier, will make its MD&M West debut inthe United States. Kicking off 2024, the company presents a comprehensive range of top-quality medical-grade TPU series to the foremost expe...
2024-01-23 10:06
4528
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
GAITHERSBURG, Md., Jan. 23, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and ...
2024-01-23 06:00
3690
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
MELBOURNE, Australia, Jan. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be he...
2024-01-22 19:00
2743
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Company expects to record a total reven...
2024-01-22 07:50
5404
Call for Application for 2024 Tsinghua Amgen Scholars Program
BEIJING, Jan. 19, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thr...
2024-01-19 15:32
5456
Top Employer 2024 certification reflects Boehringer Ingelheim's impactful people development in Asia Pacific
* Boehringer Ingelheim is recognized as one of 17 Top Employers worldwide and for the fifth consecutive year inAsia Pacific * High scores in development and steering (strategy and leadership) practices highlight Boehringer Ingelheim's continued commitment to employee wellbeing and development...
2024-01-18 12:00
2703
Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024
* Octapharma will present new clinical and scientific findings for wilate® and Nuwiq® * New findings in von Willebrand disease (VWD) and haemophilia A, will be presented by leading experts in a Satellite Symposium, as well as an oral and six poster presentations * Presentations will include...
2024-01-18 02:20
2856
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansionshowed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 mg/kg do...
2024-01-17 20:00
4539
Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
CAESAREA, Israel, Jan. 16, 2024 /PRNewswire/ -- Epitomee® announces the successful completion of the RESET pivotal clinical trial, for its weight loss capsule. The randomized placebo controlled, double blind trial, investigated the safety and efficacy of Epitomee® capsule versus the sham capsule ...
2024-01-16 21:00
3210
Subject Enrollment Completed for International Multicenter Comparative Clinical (Phase 3) Study of Boan Biotech's Denosumab
A meeting was also held in Germany to announce the results of the international pharmacokinetic similarity clinical (Phase 1) study BERLIN, Jan. 12, 2024 /PRNewswire/ -- Boan Biotech recently announced that subject enrollment for the international multicenter comparative clinical (Phase 3) study...
2024-01-12 21:15
4449
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients
YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted Fast Tra...
2024-01-12 18:17
3035
CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference
SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference（"JPMHC"）2024 is taking place onJanuary 8-11 at San Fracisco,USA, members of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, Kelun-Biotech) senior management team participated in the conferen...
2024-01-11 16:32
3357
A New Study Shows GlycoMark is a Novel Biomarker of SGLT-2i Adherence
RALEIGH, N.C., Jan. 10, 2024 /PRNewswire/ -- A new study, "1,5-Anhydroglucitol: A Novel Biomarker of Adherence in Sodium -Glucose Cotransporter 2 Inhibitors," was published online onDecember 13, 2023, in Diabetes Care, a journal from the American Diabetes Association. The study was conducted b...
2024-01-10 20:00
1838
Novogene Bolsters Global Presence with Expanded PacBio Revio Fleet, Advancing Long-Read Sequencing Applications
SINGAPORE, Jan. 10, 2024 /PRNewswire/ -- Novogene further expands its long-read sequencing capacity with the acquisition of six additional PacBio Revio sequencers, augmenting its fleet of multi-platforms sequencing technology. This strategic investment underline Novogene's commitment to enhancing...
2024-01-10 10:30
4689
GBI Secures Commercial Manufacturing Contract, Solidifying Leadership in Radiopharmaceutical Manufacturing
PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing...
2024-01-09 22:00
2069
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 294 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
9534
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7924
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
7191
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
2026-09-15 19:07
6469
